1. Mitchell, AJ, Benito-León, J, González, J-MM, et al. Quality of life and its assessment in multiple sclerosis: Integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4(9): 556–566.
Google Scholar | Crossref | Medline2. Ware, JE, Sherbourne, CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–483.
Google Scholar | Crossref | Medline | ISI3. Hobart, J, Lamping, D, Fitzpatrick, R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain 2001; 124(Pt 5): 962–973.
Google Scholar | Crossref | Medline | ISI4. Pittock, SJ, Mayr, WT, McClelland, RL, et al. Quality of life is favorable for most patients with multiple sclerosis: A population-based cohort study. Arch Neurol 2004; 61(5): 679–686.
Google Scholar | Crossref | Medline5. Rudick, RA, Miller, D, Clough, JD, et al. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49(12): 1237–1242.
Google Scholar | Crossref | Medline6. Benito-León, J, Morales, JM, Rivera-Navarro, J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002; 9(5): 497–502.
Google Scholar | Crossref | Medline7. Kurtzke, JF . Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444–1452.
Google Scholar | Crossref | Medline | ISI8. Motl, RW, Cohen, JA, Benedict, R, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler 2017; 23(5): 704–710.
Google Scholar | SAGE Journals | ISI9. Feys, P, Lamers, I, Francis, G, et al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler 2017; 23(5): 711–720.
Google Scholar | SAGE Journals | ISI10. Strober, L, DeLuca, J, Benedict, RH, et al. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler 2019; 25(13): 1781–1790.
Google Scholar | SAGE Journals | ISI11. Fruehwald, S, Loeffler-Stastka, H, Eher, R, et al. Depression and quality of life in multiple sclerosis. Acta Neurol Scand 2001; 104(5): 257–261.
Google Scholar | Crossref | Medline | ISI12. Benedict, RHB, Wahlig, E, Bakshi, R, et al. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005; 231(1–2): 29–34.
Google Scholar | Crossref | Medline | ISI13. Højsgaard Chow, H, Schreiber, K, Magyari, M, et al. Progressive multiple sclerosis, cognitive function, and quality of life. Brain Behav 2018; 8(2): e00875.
Google Scholar | Crossref | Medline14. Cohen, JA, Krishnan, AV, Goodman, AD, et al. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. JAMA Neurol 2014; 71(11): 1386–1393.
Google Scholar | Crossref | Medline15. Kapoor, R, Ho, P-R, Campbell, N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 2018; 17(5): 405–415.
Google Scholar | Crossref | Medline16. Roxburgh, RHSR, Seaman, SR, Masterman, T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64(7): 1144–1151.
Google Scholar | Crossref | Medline | ISI17. Costelloe, L, O’Rourke, K, Kearney, H, et al. The patient knows best: Significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry 2007; 78(8): 841–844.
Google Scholar | Crossref | Medline18. Norman, GR, Sloan, JA, Wyrwich, KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003; 41(5): 582–592.
Google Scholar | Crossref | Medline | ISI19. Goldman, MD, LaRocca, NG, Rudick, RA, et al. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology 2019; 93(21): e1921–e1931.
Google Scholar | Crossref20. Morrow, SA, Drake, A, Zivadinov, R, et al. Predicting loss of employment over three years in multiple sclerosis: Clinically meaningful cognitive decline. Clin Neuropsychol 2010; 24(7): 1131–1145.
Google Scholar | Crossref | Medline | ISI21. Smith, SM, Zhang, Y, Jenkinson, M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 2002; 17(1): 479–489.
Google Scholar | Crossref | Medline | ISI22. R Core Team . R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2021, http://www.R-project.org/
Google Scholar23. Koch, MW, Mostert, J, Uitdehaag, B, et al. Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. Mult Scler 2020; 26(12): 1540–1549.
Google Scholar | SAGE Journals | ISI24. Koch, MW, Mostert, J, Repovic, P, et al. Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis. Neurology 2021; 96(1): e111–e120.
Google Scholar | Crossref25. Bosma, LVAE, Sonder, JM, Kragt, JJ, et al. Detecting clinically-relevant changes in progressive multiple sclerosis. Mult Scler 2015; 21(2): 171–179.
Google Scholar | SAGE Journals | ISI26. Hayton, T, Furby, J, Smith, KJ, et al. Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol 2012; 259(2): 237–245.
Google Scholar | Crossref | Medline | ISI27. Kalinowski, A, Cutter, G, Bozinov, N, et al. The timed 25-foot walk in a large cohort of multiple sclerosis patients. Mult Scler. Epub ahead of print 8 June 2021. DOI: 10.1177/13524585211017013.
Google Scholar | Crossref